Apr 10, 2020
Lilly Begins Clinical Testing of Therapies for COVID-19
Mar 27, 2020
Global Genital Herpes Pipeline Review, H1 2020
Jan 27, 2020
Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine
Jan 14, 2020
Nurx Introduces Convenient & Stigma-Free Treatment for Herpes
Jan 08, 2020
Candel Therapeutics Acquires Next-Generation Herpes Drug Development Platform and Manufacturing Expertise
Oct 29, 2019
Market Share in Nanotechnology and Nanomedicine for Treatment of Viral Infections Could Reach Tens of Billion Dollars
Aug 26, 2019
NanoViricides, Inc. Has Filed its Annual Report, Company Advancing Rapidly Towards First IND
Aug 23, 2019
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis
Aug 05, 2019
Squarex Announces Positive Results from Completed Phase 2 Study of SQX770 in the Prevention of Recurrent Herpes Labialis
Aug 05, 2019
NanoViricides Reports Its First Drug Candidate is on Track with GLP Safety/Toxicology Studies toward Human Clinical Trials
Jul 30, 2019
New Startup Biotech Company Plans to Test Promising Herpes Vaccine for Both HSV-1 and HSV-2
Jul 23, 2019
BlueWillow Biologics Awarded Patent for Intranasal Genital Herpes Vaccine
Jul 01, 2019
Squarex Appoints Biopharmaceutical Industry Veteran Jack V. Talley as Chief Executive Officer
May 29, 2019
Squarex to Present at 2019 BIO International Convention
May 02, 2019
Genital Herpes Treatment Drugs: Global Market Insights & Projections, 2016 to 2026
Apr 16, 2019
NanoViricides Submits Pre-IND Briefing Documents to the US FDA
Mar 26, 2019
NanoViricides has Requested a Pre-IND Meeting with the US FDA
Mar 05, 2019
NanoViricides Reports Excellent Safety Profile of Its First Drug Candidate in Dermal Treatment Study
Feb 27, 2019
NanoViricides Announces $2.5 Million Financing in a Registered Direct Offering
Feb 19, 2019
NanoViricides Files Quarterly Report for Period Ending December 31, 2018 - HerpeCide Drug Candidate Progressing in IND-Enabling Studies Towards Clinical Trials